ArticleClinical and translational radiation oncology2026
Pediatric CNS relapse of neuroblastoma treated with upright proton craniospinal irradiation.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Upright positioning in pediatric radiotherapy: rationale, safety considerations and a research roadmap.Technical innovations & patient support in radiation oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Craniospinal irradiation (CSI) is a technically demanding treatment in pediatric oncology, especially for young children, who often require daily anesthesia. Although proton therapy offers dosimetric advantages over photons by eliminating exit dose and reducing exposure to healthy tissues, its global availability is limited due to the cost and complexity of gantry-based systems. Recently, gantry-less proton therapy with upright positioning has recently emerged as a compact, cost-efficient alternative, integrating robotic positioning and vertical CT-based image guidance. This study reports the first pediatric case of upright proton CSI delivered under intravenous monitored anesthesia care (MAC) using such a system. A four-year-old male patient with relapsed neuroblastoma in the central nervous system received CSI at a dose of 18.0 Gy(RBE) in 12 fractions, along with a simultaneous integrated boost (SIB) of 21.6 Gy(RBE) to the resection cavity. This was followed by a sequential boost to the resection cavity in five fractions, for a total dose of 30.6 Gy(RBE). The treatment was performed in the seated position with customized immobilization, upright volumetric CT verification, and reproducible daily setup. MAC achieved without intubation, allowing continuous airway access. The patient completed the treatment regimen without interruption, did not experience any grade 2 or higher acute toxicities, and demonstrated adequate tolerance of daily anesthesia. This case demonstrates the clinical feasibility of upright proton CSI under MAC and provides proof of concept for the broader adoption of gantry-less proton therapy in complicated cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.